Traders should monitor upcoming revenue guidance and clinic adoption metrics; the SWIFT protocol could accelerate commercial growth, especially if payer policies continue to ease. Watch for follow-on studies or additional insurance coverage changes.
Price Chart
Executive Summary
BrainsWay released new clinical data demonstrating that its FDA-cleared SWIFT™ accelerated Deep TMS protocol for major depressive disorder achieves comparable remission and response rates to the standard protocol in significantly fewer treatment days—reducing the acute phase from 20 visits to just 6 half-days. The data show an 87.8% response rate and 78.0% remission rate, with median time to remission cut from 28 to 21 days, supporting improved patient access and retention.
Key Facts
- SWIFT™ protocol reduces acute treatment phase from 20 visits over 4 weeks to 6 half-days, a ~70% reduction in clinic visits
- 87.8% response rate and 78.0% remission rate achieved with SWIFT, comparable to standard protocol
- Median time to remission decreased to 21 days vs. 28 days with standard treatment
- 70% of patients no longer had severe quality-of-life impairment; ~60% returned to normal-range functioning
- Evernorth Behavioral Health eliminated prior authorization for Deep TMS, improving payer access
Financial Impact
Potential for significantly increased treatment adoption due to reduced time burden and improved payer access, which could drive higher utilization and revenue over time
Risk Factors
- Commercial adoption may lag despite clinical success due to provider inertia or reimbursement limitations
- Forward-looking statements are subject to risks including regulatory delays, competition, and failure to scale
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249244 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $14.16 $13.63 | ▼ −3.74% | ▼ −3.08% | $12.71 (−10.24%) |
Aug 27, 2026 5w ago | 6-K | $14.40 $14.51 | ▲ +0.76% | ▲ +0.50% | $12.71 (−11.74%) |
Aug 12, 2026 7w ago | 6-K | $16.47 $14.97 | ▼ −9.11% | ▼ −7.14% | $12.71 (−22.83%) |
Aug 12, 2026 7w ago | 6-K | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Aug 12, 2026 7w ago | Press Release | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Jul 20, 2026 10w ago | 6-K | $16.50 $15.97 | ▼ −3.21% | ▼ −2.79% | $12.71 (−22.97%) |
Jul 16, 2026 11w ago | 6-K | $14.84 $16.51 | ▲ +11.25% | ▲ +12.92% | $12.71 (−14.35%) |
Jun 29, 2026 13w ago | Press Release | $15.17 $16.02 | ▲ +5.60% | ▲ +4.22% | $12.71 (−16.22%) |
Jun 22, 2026 14w ago | 6-K | $14.38 $15.17 | ▲ +5.49% | ▲ +5.95% | $12.71 (−11.61%) |
May 18, 2026 19w ago | Press Release | $14.88 $15.89 | ▲ +6.79% | ▲ +5.17% | $12.71 (−14.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access